Revenue: Revenue for the three months ended September 30, 2024, increased to approximately $1,958,000 compared to $397,000 ...

The basic experimental model tested the ability of an infusion of human ... the infused albumin in the immediate postinfusion period a comparison was made between the rise in serum protein levels ...

Drs. Pankaj Mohan, CEO of Sonnet, and John Cini, CSO of Sonnet, discuss the Company’s recent issuance of a U.S. patent covering a variant of ...

Cullinan will present new in vitro preclinical data that provide further strong rationale for broad clinical development of CLN-978 in autoimmune ...

DYAI READ THE FULL DYAI RESEARCH REPORT 3Q:24 Operational & Financial Results Dyadic International Inc. (NASDAQ: DYAI) ...

Creatinine is measured via a smartphone-based imaging system, while albumin levels are assessed with an indigenously ...

Sonnet BioTherapeutics Holdings, Inc. disclosed in an 8-K filing with the SEC on November 6, 2024, that it has successfully completed an underwritten public offering aimed at raising $5.0 million in ...

What are the latest Once Human codes? There are times in all of our gaming lives when we need a little bit of help. Call it a handout, call it a freebie, call it whatever you like, but receiving a ...

The drug candidates comprise modified versions of recombinant human interleukin-18 with the patent effective till June 2044 ... It also prolongs the biological activity of connected molecules by ...

Effects on migration of the human colonic carcinoma cell line HT-29 and rat small intestinal cell line RIE-1 were assessed using a wounded monolayer assay system (used as an in vitro model of wound ...